title: Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain.
authors.affiliation: Janssen Japan , Tokyo , Japan.
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Imanaka
authors.forename: Yushin
authors.initials: Y
authors.lastname: Tominaga
authors.forename: Mila
authors.initials: M
authors.lastname: Etropolski
authors.forename: Ilse
authors.initials: I
authors.lastname: Van Hove
authors.forename: Masaki
authors.initials: M
authors.lastname: Ohsaka
authors.forename: Mikio
authors.initials: M
authors.lastname: Wanibe
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Hirose
authors.forename: Taka
authors.initials: T
authors.lastname: Matsumura
mesh_terms: D059350:Chronic Pain / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms; D059408:Pain Management / Q000379:methods*; D010636:Phenols / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D010636:Phenols